• No results found

A Daratumumab for Delayed Red-Cell Engraftment after Allogeneic Transplantation

N/A
N/A
Info
Nedlasting
Protected

Academic year: 2022

Share "A Daratumumab for Delayed Red-Cell Engraftment after Allogeneic Transplantation"

Copied!
5
0
0

Laster.... (Se fulltekst nå)

Last ned nå ( 5 sider )

Fulltekst

Referanser

Last ned nå ( PDF - 5 sider - 172.14 KB )

RELATERTE DOKUMENTER

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous

MAIN DOCUMENT Obstructive and restrictive pulmonary dysfunction in long-term lymphoma survivors after high-dose therapy with autologous stem cell transplantation Jo S Stenehjem, Ph.D.

Obstructive and restrictive pulmonary dysfunction in long-term lymphoma survivors after high-dose therapy with autologous stem cell transplantation.. Jo S

Lifestyle behavior among lymphoma survivors after high-dose therapy with autologous hematopoietic stem cell transplantation, assessed by patient-reported outcomes

Figure 3a Proportion of lymphoma survivors after high dose therapy with autologous hematopoietic stem cell transplantation adhering to a number of lifestyle recommendations